# Paolo Marchetti

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/paolo-marchetti/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,912 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 67 |
| i10-index | 375 |
| Last Known Institution | University of the Immaculate Conception |
| OpenAlex ID | https://openalex.org/A5042989547 |
| ORCID iD | https://orcid.org/0000-0002-9064-8761 |
| Works | 1,044 |

## Researcher papers

- [A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable](https://scholariq.org/papers/a-multicenter-study-of-body-mass-index-in-cancer-patients-treated-with-anti-pd-1/)
- [Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice](https://scholariq.org/papers/integrated-analysis-of-concomitant-medications-and-oncological-outcomes-from-pd/)
- [Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions](https://scholariq.org/papers/immunotherapy-in-the-treatment-of-metastatic-melanoma-current-knowledge-and/)
- [Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab](https://scholariq.org/papers/association-of-systemic-inflammation-index-and-body-mass-index-with-survival-in/)
- [Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study](https://scholariq.org/papers/clinical-outcomes-of-patients-with-advanced-cancer-and-pre-existing-autoimmune/)
- [Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial](https://scholariq.org/papers/adjuvant-vemurafenib-in-resected-brafv600-mutation-positive-melanoma-brim8-a/)
- [Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients](https://scholariq.org/papers/correlations-between-the-immune-related-adverse-events-spectrum-and-efficacy-of/)
- [Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer](https://scholariq.org/papers/clinical-outcomes-and-toxic-effects-of-single-agent-immune-checkpoint-inhibitors/)
- [Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy](https://scholariq.org/papers/differential-influence-of-antibiotic-therapy-and-other-medications-on/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [University of the Immaculate Conception](https://scholariq.org/institutions/university-of-the-immaculate-conception/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.